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Summary
Rubella infection generally leads to mild symptoms; otherwise, 
in pregnant women it can cause severe damages. The only way to 
prevent rubella is vaccine. Before the introduction of the vaccine, 
up to 4 babies in 1000 live births were born with CRS. 
This work aims to review the most important strategies for the 
elimination of CRS in upper and high-income countries.
Papers were selected through a PubMed search up to January 
2019, using keywords rubella, congenital rubella syndrome and 
epidemiology. Articles published in the last 12 years and referred 
to upper income and high-income countries in title or abstract 
were included. 
Sixty-five papers were selected dealing with one or more of the 
following strategies: increasing of rubella vaccination coverage 
in childbearing age women, males, immigrants; exploitation of all 
appropriate occasions; improving of rubella surveillance. 
Despite numerous suggestions and indications for valid strategies 
to eliminate rubella in pregnancy and congenital rubella syn-
drome, a practical application is often missing.
Introduction
Rubella is an acute viral infection that generally leads to 
mild symptoms, such as fever and rash in children and 
adults. It spreads by contact with infected nasal or throat 
secretions or by breathing droplets sprayed into the air 
when an infected person sneezes, coughs or talks. In 
pregnant women, however, rubella infection can cause 
severe damages. During the first trimester, it can result 
in miscarriage, fetal death, stillbirth, or infants with con-
genital malformations, known as congenital rubella syn-
drome (CRS). These children can present eye and heart 
defects, hearing impairments and other lifelong disabili-
ties as diabetes and thyroid dysfunctions. All these are 
serious clinical conditions, with high costs in terms of 
therapy, care and disabilities [1].
The only way to prevent rubella is vaccination; before 
the introduction of the vaccine, up to 4 babies in 1000 
live births were born with CRS  [2]. The widely used 
rubella-containing vaccine (RCV) is safe and effective 
and one dose is about 97% effective in preventing ru-
bella [1].
Since the 1980s, WHO recommended national use of 
routine childhood rubella vaccination. Three World 
Health Organization (WHO) Regions (American, Eu-
ropean and Western Pacific Region) have rubella and 
CRS elimination goals  [3]. WHO, summarizing global 
progress toward rubella and CRS control and elimina-
tion, reports that as of December 2016, 152 of 194 coun-
tries had introduced RCV into their national immuniza-
tion schedule. In the WHO European Region 95% of 
53 Member countries incorporated a RCV by 2009 into 
their routine childhood immunization programs, and, in 
2010, 67% of the WHO Member States included rubella 
in association with measles vaccines in their national im-
munization programs [4-6].
Furthermore, according to WHO’s guidelines, a key 
strategy for achieving rubella elimination is the imple-
mentation of a high-quality Surveillance System. Today 
we can find Surveillance System for rubella, rubella in 
pregnancy and congenital rubella syndrome in most of 
the American, European and Western Pacific Region’s 
countries [2].
Unfortunately, despite the existence of well-established 
immunization programs and the presence of Surveillance 
Systems, in high and upper-middle income countries epi-
demiological data show that rubella, rubella in pregnancy 
and CRS still represent an important Public Health issue. 
In this scenery, a review of the existing literature was 
performed:
• to identify the most important strategies for the elim-
ination of rubella in pregnancy and CRS in high and 
upper-middle income countries; 
• to highlight aspects that can lead to an improvement 
in the fight against CRS.
Materials and methods
Papers were selected through a PubMed search up to 
January 2019, using the following keywords: rubella and 
congenital rubella syndrome and epidemiology.
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Inclusion criteria were (Fig. 1):
• papers published from 2007 to 2018;
• papers referred to high and upper-middle income 
countries [according to the New country classifica-
tions by income level: 2017-2018 by the World Bank 
(69)] in title or abstract;
• papers with abstract;
• papers in English and other languages of the Euro-
pean Community.
Full text of selected articles was evaluated and papers 
were excluded if they did not present data about national 
surveillance systems and strategies to improve vaccina-
tion coverage. 
The analysis was performed in 65 articles considering 
three topics:
• strategies to increase coverage in risk groups: women 
in childbearing age, males not included in universal 
rubella vaccination programs and immigrants;
• strategies to use every opportunity to offer immuni-
zation, like different places or situations;
• strategies to implement surveillance system consid-
ering solution for correcting underestimation, col-
laboration with laboratories and integrating measles 
and rubella surveillance.
Results
The selected papers addressed at least one of the follow-
ing strategies for the prevention of rubella in pregnancy 
and CRS: rubella vaccination coverage in childbearing 
age women, males and migrants; different opportuni-
ties to offer vaccine; problems related to rubella surveil-
lance [1, 4, 6-68].
Coverage 
Rubella vaccination coverage was considered in fifty-
one (78%) articles (Tab. I).
Rubella vaccination coverage in childbearing age 
women
Among the twenty-two selected articles that considered 
this point, many underlined that comprehensive strate-
gies are needed to prevent CRS [8, 9, 25, 31, 51, 55, 66]. 
High levels of immunity (≥ 95%) in the general popula-
tion and immunization of susceptible subjects are the 
cornerstones to prevent CRS [50].
Seroprevalence studies are useful to identify susceptible 
groups that may require additional prevention strategies 
and should be carried out periodically [25, 41]. A great 
number of childbearing age women are still unprotected 
from rubella  [6,  10,  44,  54]. Three studies in women 
of reproductive age showed that between 14 and 17% 
were susceptible to rubella  [8,  29,  66]. In Greece  [8] 
vaccination coverage was 18.5% while in China  [66] 
generally lower vaccination coverage was indicated. 
Countries should make efforts to reach women of child-
bearing age either through routine services or mass cam-
paigns [1, 38]. The priority is to reach a high coverage in 
susceptible women, offering vaccination in every occa-
sion, in particular to immigrant women [35]. 
Supplemental immunization activities are required also 
for countries, that revised their immunization strategies. 
In fact, when rubella vaccination was offered to all chil-
dren at 12 months instead of immunizing only girls at 
11-13 years of age, for some time the amount of suscep-
tible people increased in general population, and among 
them we can find women in childbearing age [25].
Catch-up programs are necessary to reach susceptible 
individuals missed in routine immunization even if vac-
cine coverage is as high as 97-99% [26] and they have 
been implemented in many countries [25]. 
Immunization strategies should be integrated with pre-
conception care  [19,  41]. When this is not possible, 
susceptible women should be vaccinated during the 
postpartum period  [10]. Females of childbearing age 
and pregnant women must be aware of mother-to-child 
transmission to reduce the incidence of CRS  [14,  46] 
and a study demonstrated that a high proportion (36%) 
of the pregnant women of the study group was unaware 
of the risk posed by rubella infection contracted during 
pregnancy [29]. 
Rubella vaccination coverage in males
For many years the prevalent vaccination strategy for ru-
bella has focused on women coverage [32]. In this way 
the male population has become a major reservoir of 
susceptible subjects in many cases [42, 58]. Therefore, 
to interrupt endemic rubella transmission, supplemen-
tary immunization activity should be focused on male 
adults  [43,  62]. For example, three countries (Chile, 
Brazil and Argentina) focused campaign between 1999 
and 2006 on women and transmission and outbreaks of 
rubella mainly occurred among adolescent and adult 
males  [12]. Therefore, the immunization strategy was 
focused on males starting in 2007. In Brazil it was shown 
that the greater incidence in men lead to new outbreaks 
of CRS [39]. In Mexico and Costa Rica no cases of CRS 
have been recorded since 2008, thanks to a universal 
vaccination strategy [6, 39].
In the American Region, in countries that had vaccinated 
only women during mass campaigns, outbreaks of ru-
bella occurred in 2007 despite a reduction of 97.8% of 
confirmed cases [13]. 
In Europe, many countries introduced rubella vaccine in 
females earlier than in males. In Catalonia, it was shown 
that infected males had contact with potentially pregnant 
females of the same age and therefore males became the 
target of specific vaccination campaigns [34].
Poland and Romania, as a result of a strategy that ini-
tially focused on females, experienced rubella outbreaks 
that predominantly affected males in 2012  [1]. In Po-
land, the selective vaccination of adolescent girls since 
1989 explains the 81% of cases among 15-29 year-old 
males during the outbreak in 2013 [41]. 
In Japan, there has been a large outbreak of rubella in 
2012-2013 and most cases were reported in males (aged 
20-49 years). The following year Tokyo Metropolitan 
Government began offering free (or reduced cost) vacci-
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nations to females of childbearing age and their partners 
as a response to the outbreak [56]. 
Rubella vaccination coverage in immigrants
Vaccination policies are not common to all countries. 
In particular, rubella is not a priority for many of the 
migrants’ countries of origin  [33] and generally the 
percentage of seronegativity is higher in foreign born 
women, especially those from Asia [23]. In a large study 
performed in Ireland rubella susceptibility was 6% in 
European mothers and 11.4% in women born outside the 
European Union [40].
Immigrant women, who presently represent the popula-
tion with higher fertility [28] and that are one of the most 
vulnerable and frequently neglected groups, represent a 
priority for rubella vaccination [7, 10, 32].
Rubella elimination in Europe, may be obtained also 
through the control of transmission form countries with 
high incidence [25]. 
In UK most of the recent cases of CRS have been ob-
served in infants of foreign born mothers because of the 
lack of vaccination programs or sub-optimal coverage in 
their countries of origin [59]. Further attention is needed 
to respect the catch-up program after entering the UK [9]. 
Other important occasions of transmission can be the visit 
of relatives and friends from endemic countries [64].
Pregnant women who return to their countries of origin 
with endemic virus circulation may be on danger (i.e. 
Nigeria) [63]. 
Women from countries that do not have specific immu-
nization programs for rubella may give birth to an infant 
with CRS [19, 68]. For preventing CRS in immigrants, 
Fig. 1. Flow chart for articles selection.
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a Canadian study proposes the possibility to offer vacci-
nation to women of childbearing age after investigating 
their immune status or immediately without serological 
control [18].
Similarly, an Italian study proposes vaccination of for-
eign-born women at their first encounter with the health-
care system  [35] especially considering that in recent 
years in Italy there has been an increased number of 
immigrant women (to joint family members) and also a 
large number of women employed as care providers or 
domestic workers [45].
Appropriate occasions
Eighteen of the selected articles (28%) consider this 
point (Tab. II).
It is important to take advantage of every opportunity of 
encounter with the health system to inform about risks 
of CRS and provide an active vaccination offer to sus-
ceptible women in childbearing age in different loca-
tions and situations [14, 29, 48]. Several strategies have 
been suggested to increase the achievement of vaccine 
offer in susceptible: 
Tab. I. Strategies for preventing rubella and CRS – Coverage.
References Authors / Strategies Coverage
Childbearing age women Males Immigrant
7 Bonanni 2007     x
8 Giuola 2007 x    
9 Jin 2007 x   x
10 Rota 2007 x   x
12 CDC 2008   x  
13 Weekly epidemiological record 2008   x  
14 Canepa 2009 x    
18 McElroy 2009     x
19 Pandolfi 2009 x   x
23 Hernandez Diaz 2011     x
25 Usonis 2011 x   x
28 Bechini 2012     x
29 Calimeri 2012 x    
31 Metcalf 2012 x    
32 Song 2012   x x
33 Tkadlecova 2012     x
34 Barrabeig 2013   x  
35 Bechini 2013 x   x
38 Cutts 2013 x    
39 Mongua Rodriguez 2013   x  
40 O’Dwyer 2013     x
41 Paradowska-Stankievicz 2013 x x  
6 Bouthry 2014 x x  
42 Grangeot-Keros 2014   x  
43 Yamada 2014 x x  
44 Khandaker 2014 x   x
45 Lo Giudice 2014     x
46 Morioka 2014 x    
48 Cozza 2015 x    
50 Giambi Filia 2015 x    
51 Jyoti 2015 x    
1 Lambert 2015 x x  
54 Neu 2015 x    
55 Plans 2015 x    
56 Sugishita 2015   x  
58 Kinoshita 2016   x  
59 Ogundele 2016     x
62 Mori 2017   x  
63 Baltimore 2018 x   x
64 Bukasa 2018     x
66 Meng 2018 x    
68 Seppälä 2018     x
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School and work place
Considering the most appropriate age for vaccination 
(target age group 10-14), the school may be a privileged 
place for the promotion [44]. Vaccination of school per-
sonnel could also be an opportunity to explore  [35]. 
Mass vaccination is essential to eliminate rubella trans-
mission at workplaces. In a rubella epidemic in March 
2013 in Tokyo, the workplace was the most frequent lo-
cation of transmission, among adults. The Tokyo Metro-
politan Government provided financial support for adult 
MR vaccination to local administrations for 1 year [56].
Visit at the travel medicine service
Vaccination of susceptible people visiting foreign coun-
tries could be an opportunity [25, 48]. Susceptible preg-
nant women should evaluate the danger of travelling to 
countries where rubella is endemic [44]. 
Post-partum [10, 16, 23, 54, 68] and post abortion 
vaccination of susceptible women [29, 35, 67] 
It is an opportunity to increase vaccination coverage 
against rubella and other vaccine-preventable diseases 
and strategy to protect women and consequently prevent 
CRS [57].
An Italian research showed 16% of susceptibility to 
rubella in a two-year period (2014-15) among women 
accessing voluntary termination of pregnancy in Rome. 
Among them, only 15% accepted the vaccine [67]. 
In the Italian national elimination plan, several strategies 
have been proposed for post-partum vaccination. Vac-
cination of the susceptible women could be performed 
before discharge from the ward [29, 50]; or the public 
vaccination service could take care of the active call and 
immunization; or the first access of the newborn to the 
vaccination service could be exploited to vaccinate also 
the susceptible mother [50]. 
Many hospitals offer rubella immunization to women 
not immune for rubella and this strategy was generally 
shown to be effective. However, a poor adherence to the 
second dose has been reported [35, 50, 57].
A Japanese study has shown that despite knowledge of 
the risk of contracting rubella in pregnancy, women do 
not get vaccinated. Japanese guidelines recommended 
to investigate the immune status of women during preg-
nancy and to vaccinate those with low titer in postpar-
tum [43]. 
Other occasions
It is important however to be able to exploit any access 
to the vaccination services. In Italy, for example, some 
studies propose to exploit the opportunity of HPV im-
munization session or the routine anti-tetanus–diphthe-
ria–pertussis booster dose [28, 48]. 
In addition, the occasion of the screening tests can be 
exploited like the first pap-test screening visit at 25 
years [28, 29, 48].
In addition is always crucial to improve awareness of 
clinicians and of healthcare workers because of the role 
played by general practitioners, health personnel and 
specialists involved in women’s health [14, 22, 29, 68].
Surveillance
Fifty-three of the selected articles (81%) consider this 
point (Tab. III).
The problem of underestimation
Despite the awareness about the importance of notifi-
cation in a high-quality Surveillance System, there is a 
Tab. II. Strategies for preventing rubella and CRS – Opportunities.
References Authors / Strategies Opportunities
School 
and work 
place
Travel 
medicine
Post partum
post 
abortion
Vaccination 
session
First 
PAP test
Education of 
clinicians
10 Rota 2007     x      
14 Canepa 2009           x
16 Lugner 2009     x      
22 Gross-Galiano 2011           x
23 Hernandez Diaz 2011     x      
25 Usonis 2011   x        
28 Bechini 2012       x x  
29 Calimeri 2012     x   x x
35 Bechini 2013 x   x      
43 Yamada 2014     x      
44 Khandaker 2014 x x        
48 Cozza 2015   x   x x x
50 Giambi Filia 2015     x      
54 Neu 2015     x      
56 Sugishita 2015 x          
57 Vilajeliu 2015     x      
67 Pettinicchio 2018     x      
68 Seppälä 2018     x     x
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problem of rubella underestimation due to the variable 
clinical pattern and to an incomplete reporting, espe-
cially in the private sector  [11]. Some documents deal 
especially with the fundamental importance of harmo-
nizing the notification by using standard documents 
for reporting, introducing the zero-reporting and guar-
anteeing the notification from regional to central lev-
el [49, 50, 53, 56]. 
CRS is typically underestimated [61], not only because 
of the lack of notifications. In fact, cases of CRS may go 
under-recognized due to the asymptomatic nature of ru-
bella infection in mothers and a late onset of CRS symp-
toms in infants and children [25].
Even if CRS is often a severe disease with specific 
symptoms (Gregg’s triad) [15], it may present with other 
manifestations like thrombocytopenic purpura, encepha-
litis  [56]. Rubella infection during pregnancy may be 
asymptomatic or can cause abortion [19]. 
WHO proposes retrospective search into hospital re-
cords as a complementary approach to the surveillance 
of congenital rubella. However, in most countries only 
the codes referring to the most severe types of congeni-
tal rubella syndrome are considered (deafness, cataracts, 
heart defects) while the milder, asymptomatic and late-
onset cases go unnoticed [11]. In many cases even abor-
tions, stillbirths and fetal deaths are neglected [49, 50]. 
For this reason, it is mandatory to involve pediatri-
cians, obstetricians, cardiologists, ophthalmologists 
and otolaryngologists in the surveillance  [36], with 
the recommendation to investigate all pregnant women 
with fever and rash [37], to follow and record the preg-
nancy outcomes  [52] and to report all the suspected 
cases of CRS  [53]. It is also important the retrospec-
Tab. III. Strategies for preventing rubella and CRS – Surveillance.
References Authors / Strategies Surveillance
Underestimation of R 
and CRS
Laboratories’ 
role
Integrating MR
9 Jin 2007   x  
11 Carnicer-Pont 2008 x    
12 CDC 2008 x   x
13 Weekly epidemiological record 2008   x x
14 Canepa 2009   x  
15 Forsey 2009 x    
17 Martin 2009     x
19 Pandolfi 2009 x    
20 Bisbo de Filippis 2011   x x
21 Castillo-Solorzano 2011   x x
24 Rota 2011   x  
25 Usonis 2011 x x  
26 Zimmerman 2011 x x x
27 Zimmerman Muscat 2011 x x x
28 Bechini 2012     x
30 Goodson 2012   x  
34 Barrabeig 2013 x x  
35 Bechini 2013 x x  
36 Buffolano 2013 x    
37 CDC 2013 x   x
41 Paradowska-Stankievicz 2013   x  
6 Bouthry 2014   x x
44 Khandaker 2014     x
47 Chan 2015   x  
49 Giambi 2015 x x  
50 Giambi Filia 2015 x x  
52 Martinez-Quintana 2015 x x  
53 Masa Calles 2015 x x  
54 Neu 2015     x
55 Plans 2015     x
56 Sugishita 2015 x x  
60 Paradowska-Stankievicz 2016   x  
61 Vynnycky 2016 x    
4 Grant 2017   x  
65 Edirisuriya 2018   x  
68 Seppälä 2018 x x  
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tive search into hospital records, using a wide range of 
codes [34, 35, 68], so that even the most atypical cases 
of CRS can be recognized [26, 27]. 
Strengthening laboratories’ capacity
In a high-quality Surveillance System, laboratory role 
is fundamental, not only for the diagnosis and for the 
confirmation of the etiology [41, 52]. In fact, laboratory 
investigations can give information about: susceptibil-
ity in pregnant women  [26] or women in childbearing 
age  [49]; seroprevalence in the population and in risk 
groups [50]; success or failure of vaccine [34]; origin of 
infection through virus genotyping [6, 20, 21, 27].
Worldwide, thanks to molecular biology, surveillance 
has improved, and the number of rubella virus genotype 
sequences increased in the last fifteen years [4]. 
Despite the WHO recommendations and the existence of 
national reference laboratories, genotyping of the virus 
is still underused and needs to be increased in most of 
the member countries [24]. For strengthening CRS sur-
veillance systems it is very important to improve the lab-
oratory confirmation [9, 13, 14, 30, 35, 41, 47, 53, 68], 
that is often not adequate [25, 60]. Even in Japan where 
there is a good Surveillance System, not all rubella cases 
are laboratory confirmed [56]. 
Investigation concerning levels of rubella specific IgG 
seropositivity can provide evidence of increase or de-
crease over the years, giving an idea of how the country 
proceeds towards elimination [65]. 
Integrating measles and rubella 
surveillance 
According to different authors [6, 12, 13, 17, 21, 28, 44, 54, 
55] and CDC (Centers for Disease Control and Preven-
tion), surveillance for rubella infection benefits from in-
tegration with measles surveillance system [37]. In fact, 
the two diseases may be similar from a clinical point of 
view, and since the diagnosis is made by using the same 
laboratory testing methodology, and the vaccination is 
made by combined vaccines, WHO strongly recom-
mended the integration of measles and rubella surveil-
lance [26, 27]. 
Measles and rubella integrated surveillance system start-
ed in 1999 and took origin from the surveillance sys-
tem developed for measles. Patients suspected of having 
measles or rubella infection were searched at the same 
time for both measles and rubella IgM. PAHO (Pan 
American Health Organization) has recommended since 
1996, that all suspected IgM negative measles cases 
should be tested for rubella IgM [20].
Discussion
High vaccination coverage and Surveillance Systems are 
the cornerstones for eliminating rubella and congenital 
rubella syndrome (CRS). 
The increase of rubella vaccination coverage is the tar-
get of many published studies. However, in the literature 
few practical experiences are described and few results 
of their implementation are presented. The few available 
experimental studies show that women of childbearing 
age present obstacles in accepting vaccinations even if 
they are the most important target  [70]. Furthermore, 
seroepidemiological studies and Surveillance Systems’ 
data from high and upper-middle income countries sug-
gest that many women do not know their immune status 
regarding rubella [14, 29, 43, 44, 48, 50, 56, 67, 71].
In most situations, a combined rubella and measles vac-
cine (at least) is currently being used. This is at the same 
time an advantage because it takes the appropriate op-
portunities for both vaccines but a disadvantage for ru-
bella that ends up bringing all the fears evoked by anti-
measles vaccination.
There are other aspects to be considered, like the prob-
lem of the second dose. However, this second dose does 
not seem to be essential for the prevention of rubella. 
It has been shown by mathematical models that a cover-
age of about 80% is enough to obtain the elimination 
of rubella. A proportion of 80% is needed in all target 
groups and there is still a part of the population that is 
not immunized even in countries with high coverage. At 
present susceptible groups include women of childbear-
ing age, males not included in universal rubella vaccina-
tion programs and immigrants.
In the main risk group of women of childbearing age, we 
found out two main problems: susceptibility and a low 
level of awareness. We could face them with adequate 
health promotion campaigns. Furthermore, it is extreme-
ly important to use all the possible occasions to inform 
about the risk of contracting rubella during pregnancy, to 
investigate immune status and to actively offer vaccina-
tion against rubella. These occasions could be: precon-
ception care, post-partum or post-abortion period, chil-
dren’s routine immunization sessions, adolescent HPV 
immunization session, the first pap-test screening visit 
and the routine anti tetanus-diphtheria-pertussis booster 
dose.
For many years, the prevalent vaccination strategies for 
rubella have focused only on women coverage, turning 
men into a reservoir of susceptible subjects and, then, 
hindering elimination of rubella. For this reason, it is cru-
cial to reach these susceptible males with a supplemen-
tary immunization campaign focused on male adults.
Though a recent study estimates that approximately 
131,000 CRS deaths in low-income countries may be 
prevented by increasing vaccination coverage [72], not 
all countries in the World have vaccination policies and 
unfortunately, even if they have them, rubella is not con-
sidered a priority. Consequently, immigrants and partic-
ularly immigrant women represent an important vulner-
able group, which increase the risk of transmission of 
rubella even in those countries that achieved the elimi-
nation goal. It is essential to increase coverage among 
immigrants, through focused vaccination campaigns 
and by taking advantage of the first encounter with the 
healthcare system to verify the immune status and to of-
fer vaccination to those who are susceptible [73]. 
Some more results were obtained on Surveillance Sys-
tems. During 2000-2016, there has been an increase of 
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more than 40% in countries reporting rubella and CRS 
cases worldwide. Furthermore, in the Region of the 
Americas and in 33 of 53 countries of the European Re-
gion, the elimination of rubella has been reached since 
2015 and 2016, respectively [4].
Though these data show a decrease in the number of 
cases, the limits highlighted in Surveillance Systems are 
several. To achieve the goal of rubella and congenital 
rubella syndrome elimination, the existence of an ef-
fective and high-quality Surveillance System is cru-
cial [7, 14, 25, 57, 71, 74]. A Surveillance System is cur-
rently active in most of the countries in the World and, 
particularly, in the European Region [50, 53, 75]. But, 
according to data from CDC, WHO and different au-
thors [27, 48], many of these Surveillance Systems “do 
not meet the standard surveillance performance indica-
tors recommended for monitoring progress towards and 
verification of [...] rubella elimination” [76], leading to 
a serious problem of underreporting and, consequently, 
underestimation [77].
The underestimation of rubella, rubella in pregnancy and 
particularly of CRS is not only due to the lack of notifica-
tions. In fact, cases may go under-recognized because of 
the wide range of clinical manifestations of CRS and the 
asymptomatic nature of rubella infection in adults. The 
solution for this problem could be the education of all 
healthcare workers, in order to investigate all pregnant 
women with fever and rash, following and recording the 
pregnancy outcomes [14, 22, 29, 48]. Moreover, it could 
be helpful a retrospective search into hospital records us-
ing a wide range of codes, so that even the most atypical 
cases of CRS could be recognized. Furthermore, from 
a clinical point of view, rubella can be confused with 
measles. For this reason, WHO recommends the integra-
tion of measles and rubella surveillance.
Obviously, it is desirable to overcome the differences 
among the Surveillance Systems. Although they have 
been shaped on identical guidelines, the countries’ Sur-
veillance Systems are different in some aspects  [28]. 
First of all, “rubella surveillance across Europe is com-
plicated by the different methods used to collect data in 
each country [...]” [25]. The most important difference 
concerns the case definition of congenital rubella: only 
in some countries the asymptomatic congenital infection 
fits in the definition of congenital rubella and, therefore, 
is reported [11]. Furthermore, not all countries collect in-
formation about the origin (autochthonous or imported) 
of the cases [49]. These differences create difficulties in 
comparing the situation among countries, and therefore 
in interpreting the progress in the elimination process. 
Possible solutions to all these problems are the stan-
dardization of Surveillance Systems, following WHO 
guidelines. Is mandatory to strength laboratories’ ca-
pacity, to create a Surveillance System in those coun-
tries which still do not have it [27, 78] and to improve 
the existing ones in all countries across Europe and the 
World [30, 39, 49]. 
In conclusion, in addition to the possible strategies 
(routine childhood vaccination programs, mass rubella 
immunization campaigns, surveillance of childbear-
ing age susceptible women, surveillance of imported 
cases, rapid response to outbreaks  [38], strengthening 
of CRS surveillance  [17,  19], improvement of labora-
tory test results) other measures could improve the re-
sults and might help elimination efforts. For example: 
simplified handling and simplified storage of the vaccine 
may help in specific contexts [30]. Another focal point 
to reach elimination is to adapt public health strategies 
to local culture and customs  [22] and building public 
confidence and demand for vaccination [38]. Awareness 
about the risk of rubella in pregnancy is crucial among 
women in childbearing age and among health care work-
ers that must be ready to stimulate patient attention on 
subject. This could also help to reduce costs associated 
with prenatal care [14, 22, 29, 48, 71, 79]. It seems also 
important to establish clear serological screening guide-
lines including health care workers and students in train-
ing [79, 80].
Conclusions
The risk of contracting rubella in pregnancy is known, 
even a famous writer exploits it as a motive for a murder 
in her book (The Mirror Crack’d from Side to Side by 
Agatha Christie) [81]. However, despite the widespread 
awareness of its danger, there continue to be women who 
underestimate the risk and health care workers who do 
not give adequate attention to this problematic. Tools to 
solve this problem exist, however it is a common prob-
lem not to be able to solve it. Concrete interventions of-
ten focus on response to epidemics and are mostly short-
term programs [56]. 
It emerges from this study that the applicable strategies 
are mostly known and there is an awareness of their po-
tential functioning, however much work remains to be 
done to reach the goal of elimination.
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